China OKs Hypertension Diagnostics' cardiovascular profiler:
This article was originally published in Clinica
Hypertension Diagnostics has gained the go-ahead in China to market its CVProfilor DO-2020 cardiovascular profiling system for noninvasively screening, diagnosing and monitoring the treatment of patients with cardiovascular disease. The approval comes after the company's exclusive Chinese distributor - ShenZhen Filiale ShenYong Medical-Pharmacal Co - received the okay from the Chinese State Drug Administration to import and market the system. Some 40% of deaths in China result from heart disease or strokes, says St Paul, Minnesota-based Hypertension Diagnostics.